Takanori Koike, Ph.D.
Dr. Koike worked in drug discovery research as a medicinal chemist in the areas of oncology, metabolic disorders, urology, and immunology, and has contributed to the creation of multiple development candidates, including marketed products. He has been a member of the Microglia Research Unit since its launch and has led several in-house research projects as well as research collaborations. He assumed the present position in August 2022.
Shuichiro Kakimoto, Ph.D.
Dr. Kakimoto has worked as a researcher in many drug discovery research and development projects in the area of immunology, neuroinflammation, neuroscience, and the sensory organs, and has been involved in the creation and in-license of multiple product candidates, which have delivered more than 7 IND compounds in total, including those eventually launched. He led many in-house research projects and multiple collaborative research programs with external partners. In April 2019, he launched the Microglia Research Unit and, as head of the unit, led the establishment of a drug discovery platform and pipeline on pattern recognition receptors. He assumed the present position in August 2022.
WO/2021/193897, PCT/JP2021/012773, (EN) SUBSTITUTED PYRIDAZINE COMPOUND
[Novel NLRP3 inflammasome inhibitors]